[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100458741":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":32,"locations":41,"responsibleParty":63,"collaborators":10,"id":66,"slug":10,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":10,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":10,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":10,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Shaare Zedek Medical Center","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Carriers of Gaucher disease",null,"Family of patients with Gaucher disease, sequenced for the GBA1 gene.",[13],"Diagnostic Test: The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.",{"label":15,"type":10,"description":16,"interventionNames":17},"Gaucher patients","Patients from the Gaucher clinic in Shaare Zedek Medical Center, Jerusalem, Israel",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Healthy controls","Family members of Gaucher patients who are not carriers of Gaucher disease",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"DIAGNOSTIC_TEST","The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.","Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease",[9,15,19],[29],{"name":30,"affiliation":5,"role":31},"Ari Zimran, MD","PRINCIPAL_INVESTIGATOR",[33,37],{"name":30,"role":34,"phone":35,"phoneExt":10,"email":36},"CONTACT","+972-509149149","azimran@gmail.com",{"name":38,"role":34,"phone":39,"phoneExt":10,"email":40},"Michal Becker- Cohen, M.Sc.","+972-504606310","michalbec@gmail.com",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Michal Becker- Cohen","RECRUITING","Jerusalem","Please Select...","9103102","Israel","IL",{"type":51,"coordinates":52},"Point",[53,54],35.21633,31.76904,{"lat":54,"lon":53},[57,60,61],{"name":58,"role":34,"phone":59,"phoneExt":10,"email":36},"Ari Zimran, M.D.","+97226555143",{"name":38,"role":34,"phone":59,"phoneExt":10,"email":40},{"name":62,"role":31,"phone":10,"phoneExt":10,"email":10},"Ari Zimran, Prof.",{"type":31,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Ari Zimran","Prof.","100458741",false,"NCT05253560","Prodromal Parkinsonian Features in GBA1 Mutation Carriers","Inclusion Criteria:\n\n* Willing to participate\n\nExclusion Criteria:\n\n* PD patients\n* Dementia",true,"ALL","40 Years","75 Years",{"count":76,"type":77},600,"ESTIMATED","OBSERVATIONAL","Objective of the trial. To define a sub-population which is at increased risk of developing Parkinson, beyond the fact of carrying Gaucher; in this sub-population the investigators shall conduct a comprehensive evaluation that includes a variety of non-invasive tests, whose purpose is to evaluate the state of the pre- Parkinson's disease signs, signs which can appear, even twenty years before the appearance of the disease, and also to compare them to a group of diagnosed Gaucher patients and a group of healthy people who are not carriers of Gaucher disease.\n\nA group of those carriers will be available for trial or for treatment, if there will be a medicine for the prevention of the development of Parkinson, obtainable.",[81,82],"Gaucher Disease, Type 1","Healthy","2026-04-23",{"date":85,"type":86},"2026-04-29","ACTUAL",{"date":88,"type":86},"2017-05-16",{"date":90,"type":77},"2030-12-31",{"name":5,"class":6},1]